On a relative basis, the stock has outperformed the S&P 500 by 5.46% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.29% in the last 1 week, and is up 10.07% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 5.27% and the 50-Day Moving Average is 10.3%.
Celldex Therapeutics (NASDAQ:CLDX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.49 and $4.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.70. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.70, notching a gain of 4.91% for the day. The total traded volume was 1,563,678 . The stock had closed at $4.48 on the previous day.
The company Insiders own 4.2% of Celldex Therapeutics shares according to the proxy statements. Institutional Investors own 85.68% of Celldex Therapeutics shares. In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Sr. VP & CFO) of Celldex Therapeutics, Inc., Catlin Avery W had sold 25,000 shares worth of $450,000 in a transaction dated November 23, 2015. In this transaction, 25,000 shares were sold at $18 per share.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.